Dogwood Therapeutics, Inc. (DWTX) Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Dogwood Therapeutics, Inc. NASDAQ:DWTX Healthcare · Biotechnology
Mkt Cap $42.07M
EV -
SI 1.2%
Net Cash/Sh -
Prev close $1.06 +0.94%Open $1.07 +2.84%Now $1.10 VOL 82K $ Vol $93K RVOL 0.78x
Mkt Cap $42.07M
EV -
VOL 82K sh
$ Vol $93K
RVOL 0.78×
SI 1.2%
Net Cash/Sh -
Press Release
Dogwood Therapeutics Announces Third Quarter 2026 Financial Results
Dogwood Therapeutics reported Q3 2026 net loss of $4.9 million ($0.14 per share), with $0.1 million in first-ever licensing revenue from the PRIDCor agreement. The Halneuron Phase 2b trial in chemotherapy-induced neuropathic pain is fully enrolled with 239 patients, and top-line results are expected this November — the company's key near-term catalyst. Dogwood closed a $5 million private placement with its largest shareholder Sealbond Limited (a CK Life Sciences subsidiary); combined with $4.9 million of cash, runway extends only through Q1 2027.
• 12d ago AI analysis › Press Release
Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
Dogwood Therapeutics announced a $5 million private placement from a subsidiary of its largest shareholder, CK Life Sciences, at $1.22 per share — 4,098,360 shares with no warrants or derivatives, priced at-the-market under Nasdaq rules. Proceeds fund Phase 3 preparatory activities for Halneuron® in chemotherapy-induced neuropathic pain and extend the operational runway through March 2027. The financing lands weeks before topline HAL-CINP Phase 2b data (239 patients, ~25 U.S.
• 29d ago AI analysis › Press Release
Dogwood to Participate in the 2026 Maxim Growth Summit
Dogwood Therapeutics announced management will participate in the 2026 Maxim Growth Summit on October 12-14 in New York. CEO and Chairman Greg Duncan will hold one-on-one meetings with institutional investors and Maxim research analysts; portions of the event will be streamed online.
• 1mo ago AI analysis › Press Release
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
Dogwood Therapeutics completed enrollment of 239 patients in its Phase 2b HAL-CINP trial of Halneuron for chemotherapy-induced neuropathic pain, reaching the top of the planned enrollment target range. Topline data are expected in November 2026. The randomized trial is running at approximately 25 U.S. sites, with the primary endpoint being the change from baseline to week four in weekly average daily pain intensity scores.
• 2mo ago AI analysis › Press Release
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
Dogwood Therapeutics announced it will host a virtual KOL event on September 1, 2026, to discuss positive interim results from its ongoing Phase 2b trial of Halneuron® for chemotherapy-induced neuropathic pain. The company confirmed that Halneuron® has been tested on over 800 patients to date and that the ongoing Phase 2b study is evaluating 210 to 240 patients across approximately 25 U.S. sites.
• 3mo ago AI analysis › Press Release ● Major
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
Dogwood Therapeutics reported a Q2 net loss of $11.5 million, or $0.34 per share, with cash on hand of $9.6 million, which management confirms provides runway through the Phase 2b top-line readout expected in fall 2026. The company remains on track with its Halneuron Phase 2b trial for Chemotherapy Induced Neuropathy, having enrolled 217 patients with interim data showing separation from placebo; a long-term extension study has also commenced. Additional corporate developments include a partnership for legacy antiviral assets with a potential value of up to $100M and the appointment of Iain Dukes, D.Phil.
• 3mo ago AI analysis › Press Release ● Major
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
Dogwood Therapeutics announced the enrollment of the first 200 patients in its ongoing Phase 2b HAL-CINP trial evaluating Halneuron for chemotherapy-induced neuropathy. An independent data review indicated that Halneuron-treated patients are demonstrating separation from placebo in terms of pain improvement, with a low dropout rate of 4.5% compared to FDA-approved chronic pain benchmarks. The study remains on track for top-line data readout in the fall of 2026, targeting total enrollment of approximately 210 to 240 patients across 25 U.S.
• 3mo ago AI analysis › Press Release
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Dogwood Therapeutics appointed Iain Dukes, a Venture Partner at OrbiMed and former Merck and Amgen executive, as Chair of its newly formed Scientific Advisory Board. Dr. Dukes will provide strategic guidance on the company's pipeline, leveraging his deep experience in ion channel therapeutics relevant to the lead asset Halneuron.
• 4mo ago AI analysis › Press Release
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Dogwood Therapeutics announced the commencement of a 12-week open-label extension study for its lead asset Halneuron in chemotherapy-induced neuropathic pain (CINP). The decision follows a positive interim assessment of the ongoing Phase 2b double-blinded study, which showed a treatment effect versus placebo in 97 patients and a dropout rate under 5%.
• 6mo ago AI analysis › Press Release ● Major
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
globenewswire.com • 6mo ago Press Release
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Dogwood Therapeutics announced it will report its first quarter 2026 financial results before the market open on Thursday, May 14, 2026. The company's pipeline includes two first-in-class candidates, Halneuron and SP16 IV, with Halneuron currently in Phase 2b development for chemotherapy-induced neuropathic pain. CK Life Sciences Int’l., (Holdings) Inc.
• 6mo ago AI analysis › Press Release
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
Dogwood Therapeutics partnered with PRIDCor to globally develop and commercialize its antiviral candidates IMC-1 and IMC-2, shifting future development and commercialization costs to the partner. Under the agreement, Dogwood is eligible for potential payments capped at $100 million, tiered royalties up to 15%, and 9% of future capital raised or milestone payments related to the assets.
• 6mo ago AI analysis › Press Release ● Major
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
globenewswire.com • 7mo ago